Thomas Gad Sells 4,000 Shares of Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) insider Thomas Gad sold 4,000 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $22.79, for a total value of $91,160.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Thomas Gad also recently made the following trade(s):

  • On Monday, June 3rd, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.03, for a total value of $80,120.00.
  • On Tuesday, May 28th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.21, for a total value of $121,260.00.
  • On Monday, May 13th, Thomas Gad sold 6,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $20.61, for a total value of $123,660.00.
  • On Thursday, April 11th, Thomas Gad sold 250,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $25.89, for a total value of $6,472,500.00.

Shares of NASDAQ:YMAB opened at $21.89 on Friday. Y-mAbs Therapeutics, Inc has a 1 year low of $15.17 and a 1 year high of $31.00. The stock has a market cap of $733.45 million and a P/E ratio of -14.59. The company has a current ratio of 13.30, a quick ratio of 13.30 and a debt-to-equity ratio of 0.02.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Friday, March 22nd. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.11). Research analysts expect that Y-mAbs Therapeutics, Inc will post -1.95 EPS for the current fiscal year.

A number of large investors have recently made changes to their positions in the stock. Citigroup Inc. purchased a new stake in Y-mAbs Therapeutics during the 4th quarter valued at about $37,000. Strs Ohio purchased a new stake in Y-mAbs Therapeutics during the 4th quarter valued at about $38,000. BNP Paribas Arbitrage SA purchased a new stake in Y-mAbs Therapeutics during the 1st quarter valued at about $38,000. New York State Common Retirement Fund purchased a new stake in Y-mAbs Therapeutics during the 1st quarter valued at about $63,000. Finally, American International Group Inc. purchased a new stake in Y-mAbs Therapeutics during the 4th quarter valued at about $93,000. 24.80% of the stock is currently owned by institutional investors.

YMAB has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $40.00 price target (up from $36.00) on shares of Y-mAbs Therapeutics in a research report on Monday. Zacks Investment Research raised Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, March 15th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $30.80.

TRADEMARK VIOLATION WARNING: “Thomas Gad Sells 4,000 Shares of Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Stock” was originally published by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.themarketsdaily.com/2019/06/14/thomas-gad-sells-4000-shares-of-y-mabs-therapeutics-inc-nasdaqymab-stock.html.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Article: Why investors pay attention to retained earnings

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.